Freenome Inc. (FRNM)
Freenome Inc. (FRNM) Stock Price, Analysis & Data
Aucune donnée disponible
| Cours acheteur | 13.02 |
| Capitalisation boursière | 1.38B |
| Chiffre d’affaires (ttm) | 34.24M |
| Résultat net (ttm) | -225.03M |
| Bêta | 0.35 |
| EPS (ttm) | -2.07 |
| Ratio P/E (ttm) | n/a |
| P/E prévisionnel | -5.02 |
| P/B (ttm) | -0.26 |
| P/S (ttm) | 40.29 |
| Earnings Date | n/a |
| Cours vendeur | 11.17 |
| Volume | 1,893,156 |
| Volume moy. (20D) | 372,298 |
| Ouverture | 11.50 |
| Clôture précédente | 11.56 |
| Fourchette du jour | 11.49 - 13.16 |
| Intervalle de 52 semaines | 9.95 - 14.47 |
| Analyste | n/a |
| Objectif de prix | n/a |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de FRNM
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect ...
Performance financière
En 2025, le chiffre d’affaires de Freenome s’élevait à 30.41M, soit une hausse de 955.14% par rapport aux 2.88M de l’année précédente. Le bénéfice s’élevait à -219.34M, soit une baisse de -20.07%.
États financiers
2 semaines il y a · Investor's Business Daily
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 OutlookGuardant Health is Thursday's IBD Stock Of The Day in a thriving market for colon cancer screening tests. On Friday, Guardant Health stock surged after the company raised full-year outlook after a Q2...